Bioextrax AB (SE:BIOEX)
:BIOEX
Want to see SE:BIOEX full AI Analyst Report?
Top Page
Bioextrax AB
(BIOEX)
Select Model
Select Model
Rating:52Neutral
Price Target:
kr2.50
▼(-21.63% Downside)
Action:ReiteratedDate:02/20/26
The score is held back primarily by weak financial performance (persistent losses, negative gross profit in most years, and ongoing/free cash flow burn that worsened in 2025), with only the debt-free balance sheet offering meaningful support. Technicals are a key positive (price above major moving averages with positive MACD and RSI), but valuation is constrained by negative earnings (negative P/E) and no available dividend yield.
Positive Factors
Debt-free balance sheet
Zero reported debt materially reduces refinancing and interest-rate risk, giving management meaningful financial flexibility during multi-year R&D and commercialization cycles typical in industrial biotech. This lowers the immediate need for costly financing, supporting project continuity and partnership negotiations over the next 2–6 months.
Negative Factors
Negative gross profit persistency
Negative gross profit indicates the core process economics are not yet commercially viable at current scale. Unless unit costs fall or realized pricing improves, persistent negative gross margins will continue to consume capital, hinder margin sustainability, and limit the company’s ability to scale or invest in commercialization over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt materially reduces refinancing and interest-rate risk, giving management meaningful financial flexibility during multi-year R&D and commercialization cycles typical in industrial biotech. This lowers the immediate need for costly financing, supporting project continuity and partnership negotiations over the next 2–6 months.
Read all positive factors
Bioextrax AB (BIOEX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr126.62M
Dividend YieldN/A
Average Volume (3M)82.14K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth46.99%
EPS Growth16.83%
CountrySE
Employees14
SectorIndustrials
Sector Strength72
IndustryWaste Management
Share Statistics
EPS (TTM)-0.11
Shares Outstanding47,601,730
10 Day Avg. Volume104,394
30 Day Avg. Volume82,137
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)5.23
Price to Sales (P/S)146.53
P/FCF Ratio-4.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr5.34M
Bioextrax AB Business Overview & Revenue Model
Company Description
Bioextrax AB (BIOEX) is a Swedish biotechnology company that focuses on developing and commercializing environmentally sustainable technologies for converting waste materials into valuable products. The company operates in the sectors of bio-based...
How the Company Makes Money
Bioextrax makes money primarily by commercializing its industrial biotechnology capabilities and resulting products and/or process technologies. Key revenue streams can include (i) sales of bio-based products or ingredients produced using its proc...
Bioextrax AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 757.00K | 515.00K | 2.06M | 395.00K | 275.76K |
| Gross Profit | -18.37M | -915.00K | 718.00K | -18.64M | -11.29M |
| EBITDA | -17.24M | -16.18M | -20.65M | -18.19M | -10.18M |
| Net Income | -17.70M | -17.34M | -21.51M | -18.67M | -10.53M |
Balance Sheet | |||||
| Total Assets | 24.73M | 29.00M | 22.52M | 37.92M | 12.64M |
| Cash, Cash Equivalents and Short-Term Investments | 3.93M | 17.27M | 13.40M | 27.53M | 8.98M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.51M | 2.94M | 1.98M | 6.15M | 5.14M |
| Stockholders Equity | 21.21M | 26.06M | 20.54M | 31.77M | 7.50M |
Cash Flow | |||||
| Free Cash Flow | -26.20M | -18.99M | -24.41M | -24.38M | -9.45M |
| Operating Cash Flow | -26.05M | -18.78M | -23.31M | -17.60M | -8.48M |
| Investing Cash Flow | -152.00K | -215.00K | -1.10M | -6.78M | -975.13K |
| Financing Cash Flow | 12.86M | 22.86M | 10.28M | 42.94M | 16.38M |
Bioextrax AB Technical Analysis
Negative
3.19
Price Trends
2.79
Negative
2.45
Positive
2.76
Negative
Market Momentum
-0.05
Positive
45.56
Neutral
58.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOEX, the sentiment is Negative. The current price of 3.19 is above the 20-day moving average (MA) of 2.63, above the 50-day MA of 2.79, and above the 200-day MA of 2.76, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 45.56 is Neutral, neither overbought nor oversold. The STOCH value of 58.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOEX.
Bioextrax AB Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
54 Neutral | kr109.30M | -30.31 | -1.58% | ― | 5.08% | 47.38% | |
53 Neutral | kr106.59M | -13.81 | -17.60% | ― | 58.33% | 80.04% | |
52 Neutral | kr126.62M | -6.27 | -94.54% | ― | 46.99% | 16.83% | |
49 Neutral | kr40.05M | -2.71 | -25.32% | ― | ― | ― | |
47 Neutral | kr109.39M | 22.14 | 5.40% | ― | 11.12% | -10.77% | |
46 Neutral | kr204.91M | -2.12 | -20.69% | ― | -81.53% | -634.82% |
* Industrials Sector Average
SE:BIOEX
Bioextrax AB
2.66
0.26
10.93%
SE:SES
Scandinavian Enviro Systems AB
0.19
-0.69
-78.70%
SE:AXOLOT
Axolot Solutions Holding AB
0.34
-0.08
-20.00%
SE:LEVEL
Nordic LEVEL Group AB Class B
0.52
-0.07
-11.56%
SE:CIRCHE
CirChem AB
1.00
-1.59
-61.54%
SE:CLEM
Clemondo Group AB
7.90
-1.60
-16.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.